You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Medtronic
Harvard Business School
Mallinckrodt
McKesson

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 8,617,823

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,617,823
Title:Immunomodulating compositions and methods of use thereof
Abstract: The invention is directed to .beta.1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The .beta.1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The .beta.1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated .beta.1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.
Inventor(s): Rubin-Bejerano; Ifat (Belmont, MA), Fink; Gerald R. (Chesnut Hill, MA)
Assignee: Immunexcite, Inc. (Watertown, MA)
Application Number:12/990,066
Patent Claims:see list of patent claims

Details for Patent 8,617,823

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX Orphan search
Octapharma Usa Inc CUTAQUIG immunoglobulin g SOLUTION 125668 1 2019-05-03   Start Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Immunexcite, Inc. (Watertown, MA) 2028-04-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,617,823

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Dow
Boehringer Ingelheim
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.